dutogliptin

Known as: ((2R)-1-(((3R)-Pyrrolidin-3-Ylamino)Acetyl)Pyrrolidin-2-Yl)Boronic Acid 
A potent, water soluble, selective and orally bioavailable, boronic acid-based inhibitor of dipeptidyl peptidase 4 (DPP-4), with hypoglycemic… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2010-2016
02420102016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2014
Highly Cited
2014
BACKGROUND & AIMS Recently, the SAVOR TIMI-53 (Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes… (More)
  • table 1
  • table 1
  • figure 1
  • figure 2
  • table 2
Is this relevant?
2014
2014
AIM Some observational studies reporting an increased risk of pancreatitis in association with Dipeptidyl Peptidase-4 inhibitors… (More)
  • table 1
  • figure 1
Is this relevant?
2014
2014
AIMS This meta-analysis was performed to provide an update on the efficacy and safety of dipeptidyl peptidase-4 (DPP-4… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2014
2014
Dutogliptin is a selective dipeptidyl peptidase-4 inhibitor shown to be efficacious and safe in patients with type 2 diabetes… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2012
2012
Three-dimensional pharmacophore hypothesis was established based on a set of known DPP-IV inhibitor using PharmaGist software… (More)
Is this relevant?
Review
2012
Review
2012
INTRODUCTION Lipid profile is an important determinant of cardiovascular risk in type 2 diabetic patients. Available glucose… (More)
Is this relevant?
Highly Cited
2011
Highly Cited
2011
OBJECTIVE Dipeptidyl peptidase-4 inhibitors (DPP4i) have been recently associated with increased risk of pancreatitis and cancer… (More)
Is this relevant?
2010
2010
AIM To determine efficacy and tolerability of dutogliptin, a dipeptidyl peptidase 4 (DPP4) inhibitor, in patients with type 2… (More)
Is this relevant?
2010
2010
OBJECTIVE Dutogliptin is a novel, orally available, potent, and selective DPP4 inhibitor that improves glycemic control in type 2… (More)
Is this relevant?
Review
2010
Review
2010
Dutogliptin (PHX-1149T), being developed by Phenomix Corp, Forest Laboratories Inc and Chiesi Farmaceutici SpA, is a small… (More)
Is this relevant?